Regarding pCR and AEs, all these treatment regimens exhibited comparable effectiveness, especially Lapatinib+Trastuzumab and Pyrotinib+Capecitabine.<h4>Conclusion</h4>Our study highlights the prominent role of targeted therapies and immunotherapies in treating HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.